pharmacological agent

pharmacological agent

[-loj′ik]
any oral, parenteral, or topical substance used to alleviate symptoms and treat or control a disease process or aid recovery from an injury.
References in periodicals archive ?
The current lack of a pharmacological agent [to reduce visceral fat] is a really unsatisfactory situation.
By administering a pharmacological agent, the matching molecular scissors called "Cre" can be activated in the animals' hematopoietic stem cells.
disease, development), and detection of an alteration in gene expression levels in response to specific biological stimuli such as a pharmacological agent.
The US Food and Drug Administration (FDA) approved JETREA in October 2012 as the first pharmacological agent for the treatment of symptomatic VMA, a progressive, sight-threatening condition that, when left untreated, frequently leads to retinal distortion, further deterioration in vision and irreversible damage to eyesight.
In an extension of this strategy, termed pharmacological MRI (phMRI), the baseline state may be compared to conditions following administration of a pharmacological agent (e.
Reiter RJ, Tan DX, Kim SJ, Qi W, Melatonin as a pharmacological agent against oxidative damage to lipids and DNA.
Tenders are invited for Supply of Pharmacological agent to treat Gaucher disease caused by beta glucosidase enzyme deficiency in children younger than 18 years ,Pharmacological agent to treat Mucopolysaccharoidosis type 1 disease caused by alfa 1 Iduronidase enzyme deficiency in children younger than 18 years
In conclusion, each pharmacological agent has a toxicity risk depending on the dose and route of administration as well as benefits.
As an extension of this research, Wu said, it may be possible to identify a pharmacological agent or bioactive agent that may have the desired effect on this gene toward reducing obesity-related cellular inflammatory response.
When treating any patient with a pharmacological agent it is important to monitor the patient closely throughout the treatment cycle and to tailor the treatment to best fit the patient's diagnosis, lifestyle, and other health management needs.
The resulting aberrant development reflects a stage-specific sensitivity to a pharmacological agent or event.
CFTR will be crystallized alone and in the presence of the pharmacological agent Kalydeco, a small molecule from Vertex Pharmaceuticals that is used for the treatment of CF and reduces CF symptoms.

Full browser ?